Company Information

  

Address: 10182 TELESIS COURT, 6TH FLOOR  
City: SAN DIEGO 
State: CA 
Zip Code: 92121 
Telephone: 858-207-4264 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. We have several product candidates in development. LJPC-501 is our proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is our novel formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. LJPC-501 LJPC-501 is our proprietary formulation of angiotensin II.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/2017-5.09NAN/E
06/2017-5.14NAN/E
03/2017-4.84NAN/E
12/2016-4.54NAN/E
09/2016-3.79NAN/E
06/2016-3.25NAN/E
03/2016-3.05NAN/E
12/2015-2.68NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.12Total Liab/Total Assets0.14
Net Inc/Total Assets-1.10Total Liab/Inv Cap0.16
Net Inc/Inv Cap-1.28Total Liab/Comm Equity0.01
Pretax Inc/Net Sales-126.92Interest Coverage RatioNA
Net Inc/Net Sales-126.92Curr Debt/EquityNA
Cash Flow/Net Sales-95.25LTD/EquityNA
SG&A/NetSales27.11Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio6.91
Inventory TurnoverNACurrent Ratio6.91
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work Cap0.01Inv/Curr AssetsNA
Net Sales/PP&E0.20  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2016
Total Revenues(Net Sales) 0.00 0.00 0.00 0.09
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 7.39 6.02 5.50 4.83
Operating Income -26.48 -26.83 -23.27 -24.92
Interest Exp NA NA NA NA
Pretax Income -26.29 -26.73 -23.24 -24.89
Other Income 0.20 0.10 0.03 0.04
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -26.29 -26.73 -23.24 -24.89

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Cash & Short Term Investments 121.75 142.23 162.69 65.93
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 123.52 144.00 164.37 67.43
Net Property, Plant & Equipment 6.53 4.59 3.61 3.15
Total Assets 130.06 148.59 168.01 70.80
Liabilities        
Accounts Payable 10.26 8.27 5.67 9.76
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 10.26 8.27 5.67 9.76
Long-Term Debt NA NA NA NA
Total Liabilities 10.26 8.27 5.67 9.76
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 6.64 6.64 6.64 6.64
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -682.97 -656.68 -629.95 -606.71
Treasury Stock NA NA NA NA
Total Stockholders' Equity 119.80 140.32 162.33 61.04
Total Liabilities and Stockholders' Equity 130.06 148.59 168.01 70.80

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Net Cash Provided by Operating Activities -18.50 -19.79 -22.15 -18.57
Net Cash Provided by Investing Activities -2.27 -1.27 -0.75 -0.80
Net Cash Provided by Financing Activities 0.29 0.00 119.55 0.06

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.00-7.74--
12/20130.00-17.93-2062.00
12/20140.00-21.31-2.00
12/20151.06-41.91-2.68
12/20160.62-78.18-4.54
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1711124,777--




Report Date : 12/4/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.